RT Journal Article
SR Electronic
T1 Antibody response in individuals affected with Sars-Cov-2 infection: temporal trends and qualitative and quantitative differences in symptomatic and asymptomatic subjects. A Cross Sectional Analysis. Ab-Covid Study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.08.09.21261450
DO 10.1101/2021.08.09.21261450
A1 Iosief Abraha
A1 Antonella Germani
A1 Erica Pasquarelli
A1 Sofia Pascolini
A1 Rossana Antonietti
A1 Sandro Argenti
A1 Alessandra Fioravanti
A1 Elisa Martini
A1 Luana Aristei
A1 Paola Mancinelli
A1 Maria Letizia Ottaviani
A1 Martina Roselli
A1 Milena Barzacca
A1 Erika Belardinelli
A1 Marta Micheli
YR 2021
UL http://medrxiv.org/content/early/2021/08/10/2021.08.09.21261450.abstract
AB Objectives To describe clinical characteristics and treatment used in subjects who had Sars-Cov-2 infection during the first pandemic and to assess the correlation between serological titers and clinical characteristics; to evaluate the persistence of antibody titer.Design Cross-sectional study; 12 months follow-up.Setting Residents in Azienda USL Umbria 2.Participants Consecutive subjects aged 15 to 75 who were discharged with the diagnosis of Sars-Cov-2 from the hospitals of the AUSL Umbria 2, or resulted positive to a PCR test for Sars-Cov-2 infection with or without symptoms. SARS-CoV-2 serologic testing for antibodies targeting the Nucleocapside and Spike proteins were determined.Results Of 184 eligible subjects, 149 were available for evaluation: 17 were classified as Oligo/asymptomatic, 107 as Symptomatic, 25 as Hospital admitted. While fever resulted common to all the groups, headache or musculoskeletal pain was common to symptomatic participants whereas cough and dyspnea was present in all the hospital admitted. Participants with significant signs and symptoms were more likely to use antibiotics, hydroxychloroquine, heparin and steroids. Compared to Oligo/asymptomatic participants, Symptomatic and Hospital admitted participants had higher levels of anti-S titers at every follow-up (median titer at 12 month follow-up: 29 vs 94 vs 116 respectively; P < 0.001). At 12 months follow-up, anti-S titers persisted above the threshold for at least 12 months in all Hospital admitted participants, in 90% of the Symptomatic participants and 83% in the oligo/asymptomatic participants; in 30% of participants the titer raised significantly probably due to reinfection. Anti-N antibody titer tended to decrease over time and in 62% of the entire cohort resulted negative. None of the participants reported clinical reinfection with Sars-Cov-2 virus.Conclusion Anti-S and anti-N antibody titers correlates well with disease severity. Anti-S antibodies persist for at least one year and most probably provide protection from reinfection.Strengths and limitations of this studyThe key strength of this study is the evaluation of anti-Sars-Cov-2 serology using two types of serological assays and the follow-up that endured for at least 12 monthsIn addition to serological evaluation participants were also followed-up clinicallyThe study does not have a baseline serologic testing since it was conceived in late April when most of the participants were discharged from hospital or had their symptoms resolvedThe study lacks clinical and serological information regarding those who died during the pandemic event, hence we are unable to conclude whether quantitative serologic testing could predict survivalCompeting Interest StatementThe authors have declared no competing interest.Funding StatementThis study is supported by the Azienda USL Umbria 2Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Comitato Etico Regionale Umbria, CER 3695/20All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData are available upon request